Core Viewpoint - The ongoing controversy surrounding Giant Bio's collagen products has raised significant trust issues among investors and consumers, potentially impacting the company's brand reputation and financial performance [1][5]. Group 1: Company Response and Testing Results - Giant Bio has publicly stated that its products have passed regulatory checks and have undergone a three-tier verification system to ensure quality and safety [1][2]. - The company commissioned multiple authoritative testing agencies to conduct qualitative and quantitative analyses of its collagen products, adhering to industry standards [2][3]. - Despite the company's assertions, the testing methods and results have been questioned, particularly regarding the accuracy and consistency of the testing approaches used by different agencies [3][4]. Group 2: Market Impact and Financial Performance - The controversy has led to a decline in Giant Bio's stock price, which fell by 5.63% to HKD 62.9 per share, resulting in a market capitalization of HKD 673.6 billion [1]. - The sales of the company's flagship product, the collagen stick, have been substantial, with over 515 million units sold in three years, contributing significantly to revenue [5][6]. - Financial data indicates that Giant Bio's revenue has increased from CNY 2.375 billion in 2021 to CNY 5.539 billion in 2024, with net profit rising from CNY 1 billion to CNY 2.062 billion during the same period [6]. Group 3: Industry Challenges - The lack of standardized testing methods for recombinant collagen products has led to discrepancies in results from different testing institutions, exacerbating trust issues between brands and consumers [5]. - The ongoing debate over testing methods may serve as a catalyst for the establishment of industry standards, which are currently being developed by regulatory authorities [5].
明星单品陷成分“罗生门”，巨子生物检测结果再引质疑